Ontology highlight
ABSTRACT:
SUBMITTER: Waters EA
PROVIDER: S-EPMC3771085 | biostudies-other | 2012 Jul
REPOSITORIES: biostudies-other
Waters Erika A EA McNeel Timothy S TS Stevens Worta McCaskill WM Freedman Andrew N AN
Breast cancer research and treatment 20120524 2
Two selective estrogen receptor modulators, tamoxifen and raloxifene, have been shown in randomized clinical trials to reduce the risk of developing primary invasive breast cancer in high-risk women. In 1998, the U.S. Food and Drug Administration (FDA) used these studies as a basis for approving tamoxifen for primary breast chemoprevention in both premenopausal and postmenopausal women at high risk. In 2007, the FDA approved raloxifene for primary breast cancer chemoprevention for postmenopausal ...[more]